ReviewBlood advances2017
Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Review in Blood advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 69 citations in OpenAlex.
- Immune thrombocytopenia in patients with connective tissue disease.Clinical rheumatology · 2026Review
- The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK.Journal of market access & health policy · 2025Article
- Japanese database analysis: effectiveness of early initiation of TPO-RA treatment in tapering corticosteroid dose in ITP.Blood vessels, thrombosis & hemostasis · 2025Article
- A Case Series and Literature Review on Zanubrutinib Therapy for the Treatment of Relapsed/Refractory Immune Thrombocytopenia.Cancer reports (Hoboken, N.J.) · 2025Review
- Combination of anti-CD20 and hetrombopag in relapsed/refractory immune thrombocytopenia: a case series.Frontiers in medicine · 2025Article
- The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.Journal of clinical medicine · 2024Review
- Clusterin can mediate apoptosis-induced molecular mechanisms in immune thrombocytopenia.Blood vessels, thrombosis & hemostasis · 2024Article
- The first national pediatric immune thrombocytopenia registry in Iran: research protocol and preliminary study results.BMC health services research · 2024Article
- Long non-coding RNA maternally expressed gene 3, miR-125a-5p, CXCL13, and NF-kB in patients with immune thrombocytopenia.Genes and immunity · 2023Article
- Safety and Efficacy of Tyrosine Kinase Inhibitors in Immune Thrombocytopenic Purpura: A Systematic Review of Clinical Trials.Journal of xenobiotics · 2023Review
- Budget impact analysis for avatrombopag in the treatment of chronic primary immune thrombocytopenia in adult patients refractory to other treatments.Journal of market access & health policy · 2023Article
- Glucocorticoids unmask silent non-coding genetic risk variants for common diseases.Nucleic acids research · 2022Article
- Splenectomy in the management of primary immune-mediated hemolytic anemia and primary immune-mediated thrombocytopenia in dogs.Journal of veterinary internal medicine · 2022Article
- Clonal hematopoiesis in primary immune thrombocytopenia.Blood cancer journal · 2022Article
- Clinical Epidemiology, Treatment Outcome and Mortality Rate of Newly Diagnosed Immune Thrombocytopenia in Adult Multicentre Study in Malaysia.Journal of blood medicine · 2022Article
- Romiplostim in children with newly diagnosed or persistent primary immune thrombocytopenia.Annals of hematology · 2021Review
- Review
- Clinical Phenotype and Response to Different Lines of Therapy in Elderly with Immune Thrombocytopenia: A Retrospective Study.Journal of blood medicine · 2020Article
- Wilson disease associated with immune thrombocytopenia: A case report and review of the literature.World journal of clinical cases · 2019Article
- Post-Transfusion Purpura: Current Perspectives.Journal of blood medicine · 2019Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune thrombocytopenia resulting from antibody-mediated platelet destruction combined with impaired platelet production is a common cause of thrombocytopenia. The decision to treat newly diagnosed patients is based on several factors including ceasing hemorrhagic manifestations, increasing the platelet count, prevention of bleeding, and inducing remission. Current standard first-line therapy is a course of corticosteroids. Although this treatment paradigm increases the platelet count in the majority of patients, a high percentage relapse after discontinuation of corticosteroid therapy. For this reason, intensification of first-line therapy that results in superior long-term remission rates would be desirable. This manuscript focuses primarily on adults with idiopathic thrombocytopenic purpura (ITP), highlighting pediatric data and practice when applicable. The primary aim is to outline upfront strategies for treatment-naive patients with ITP to enhance remission rates, taking into account assessment of the risks and benefits of these approaches.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.